For the quarter ending 2026-03-31, VRCA had -$9,283K decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | - | 5,092 | 30,485 | - |
| Total selling, general and administrative | - | 8,117 | 27,103 | - |
| Total research and development | - | 2,520 | 6,335 | - |
| Loss on disposal of assets | - | -246 | - | - |
| Cost of product revenue | - | 2,192 | - | - |
| Cost of revenue | - | - | 2,040 | - |
| Cost of license and collaboration revenue | - | 1,249 | - | - |
| Other segment items | - | 882 | 4,819 | - |
| Net loss | -9,682 | -8,074 | -9,812 | - |
| Depreciation expense | - | - | - | 100 |
| Stock-based compensation | 897 | 686 | 718 | 1,914 |
| Depreciation expense | 17 | 14 | 23 | 96 |
| Non-cash interest expense | 0 | 400 | 716 | 1,359 |
| Loss on disposal of fixed assets | - | 0 | -68 | -178 |
| Impairment of right-of-use asset | - | 0 | - | - |
| Net loss | - | - | - | -9,538 |
| Loss on termination of financing lease | -10 | 2 | 1 | -4 |
| Amortization of operating lease right-of-use asset | 77 | 76 | 74 | 146 |
| Amortization of finance lease right-of-use asset | 100 | 100 | 87 | 165 |
| Change in obligation for r&d funding liability | - | 754 | - | - |
| Change in deferred r&d services and r&d funding liability | 1,332 | - | - | - |
| Non-cash accretion of r&d funding liability | - | - | 375 | - |
| Loss on extinguishment of debt | - | -1,533 | - | - |
| Non-cash r&d expense related to torii warrant vesting | 106 | 51 | - | - |
| Change in fair value of derivative liability | 0 | 1,762 | 34 | 852 |
| Prepaid expenses and other assets | -433 | -1,012 | 2,094 | -818 |
| Collaboration receivable, billed and unbilled | -48 | -145 | -7,896 | 8,149 |
| Inventory | -103 | - | -218 | 59 |
| Accounts payable | 121 | 487 | -736 | 425 |
| Deferred revenue | 249 | -782 | 1,083 | 481 |
| Accounts receivable | 2,464 | -1,787 | -2,146 | 9,145 |
| Accrued expenses and other current liabilities | -586 | -400 | -501 | -410 |
| Operating lease liability | -83 | -82 | -79 | -154 |
| Net cash used in operating activities | -9,163 | -4,591 | 9,685 | -22,721 |
| Purchases of property and equipment | - | 0 | 0 | 0 |
| Sale of fixed assets | - | 0 | - | - |
| Net cash used in investing activities | 0 | 0 | 0 | 0 |
| Proceeds from exercise of stock options | - | 0 | 0 | 0 |
| Debt amendment costs | - | 110 | 0 | 0 |
| Cash paid to settle debt | - | 35,030 | - | - |
| Proceeds from issuance of debt, net of issuance costs | - | 0 | - | - |
| Repayment of debt | 0 | 870 | 3,890 | 8,029 |
| Proceeds from issuance of common stock, pre-funded warrants and warrants | - | 50,067 | - | - |
| Repayment of finance lease | 111 | 106 | 94 | 183 |
| Payment of equity issuance costs | 9 | 310 | 0 | - |
| Net cash used in financing activities | -120 | 13,641 | -3,984 | -8,212 |
| Net decrease in cash and restricted cash | -9,283 | 9,050 | 5,701 | -30,933 |
| Cash and restricted cash at the beginning of the period | 30,147 | 21,097 | 46,329 | - |
| Cash and restricted cash at the end of the period | 20,864 | 30,147 | 21,097 | - |
Verrica Pharmaceuticals Inc. (VRCA)
Verrica Pharmaceuticals Inc. (VRCA)